Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

被引：0
|
作者：
Rummelt, C. [1 ]
Gorantla, S. P. [1 ]
Endres, C. [1 ,2 ]
Doehner, K. [3 ]
Meggendorfer, M. [4 ]
Heidel, F. [5 ]
Fischer, T. [6 ]
Haferlach, T. [4 ]
Duyster, J. [1 ,2 ,7 ]
von Bubnoff, N. [1 ,2 ,7 ,8 ]
机构：
[1] Uniklin Freiburg, Hamatol Onkol & Stammzelltransplantat, Innere Med 1, Freiburg, Germany
[2] DKFZ Heidelberg, Heidelberg, Germany
[3] Uniklin Ulm, Klin Innere Med 3, Ulm, Germany
[4] MLL, Munchner Leukamielabor, Munich, Germany
[5] Univ Klin Jena, Abt Hamatol & Med Onkol, Jena, Germany
[6] Otto von Guericke Univ, Med Ctr, Abt Hamatol & Onkol, Magdeburg, Germany
[7] DKTK, Freiburg, Germany
[8] UKSH Campus Lubeck, Klin Hamatol & Onkol, Lubeck, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V655
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [1] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
    Christoph Rummelt
    Sivahari P. Gorantla
    Manja Meggendorfer
    Anne Charlet
    Cornelia Endres
    Konstanze Döhner
    Florian H. Heidel
    Thomas Fischer
    Torsten Haferlach
    Justus Duyster
    Nikolas von Bubnoff
    Leukemia, 2021, 35 : 2017 - 2029
  • [2] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
    Rummelt, Christoph
    Gorantla, Sivahari P.
    Meggendorfer, Manja
    Charlet, Anne
    Endres, Cornelia
    Doehner, Konstanze
    Heidel, Florian H.
    Fischer, Thomas
    Haferlach, Torsten
    Duyster, Justus
    von Bubnoff, Nikolas
    LEUKEMIA, 2021, 35 (07) : 2017 - 2029
  • [3] Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
    Williams, A. B.
    Nguyen, B.
    Li, L.
    Brown, P.
    Levis, M.
    Leahy, D.
    Small, D.
    LEUKEMIA, 2013, 27 (01) : 48 - 55
  • [4] Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
    A B Williams
    B Nguyen
    L Li
    P Brown
    M Levis
    D Leahy
    D Small
    Leukemia, 2013, 27 : 48 - 55
  • [5] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jian-kang
    Wilson, Kelli
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2015, 126 (23)
  • [6] Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells
    Zhao, Linxiang
    Zuo, Shuwei
    Xing, Kun
    Yue, Xiaoshuang
    Zhang, Huimin
    Zhang, Jingyi
    Waxman, Samuel
    Jing, Yongkui
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML
    Wang, Aoli
    Wu, Hong
    Chen, Cheng
    Hu, Chen
    Qi, Ziping
    Wang, Wenchao
    Yu, Kailin
    Liu, Xiaochuan
    Zou, Fengming
    Zhao, Zheng
    Wu, Jiaxin
    Liu, Juan
    Liu, Feiyang
    Wang, Li
    Stone, Richard M.
    Galinksy, Ilene A.
    Griffin, James D.
    Zhang, Shanchun
    Weisberg, Ellen L.
    Liu, Jing
    Liu, Qingsong
    ONCOTARGET, 2016, 7 (20) : 29131 - 29142
  • [8] Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.
    Williams, Allen
    Nguyen, Bao
    Levis, Mark
    Brown, Patrick
    Small, Donald
    BLOOD, 2009, 114 (22) : 1452 - 1453
  • [9] Role of HDAC8 Upregulation in Resistance of FLT3-ITD AML Stem Cells to FLT3 Inhibitors
    Long, Jun
    Jia, Mingyuan
    Fang, Weiyue
    Chen, Xinjie
    Wang, Zhongyu
    Mu, Lili
    Xiang, Rufang
    Li, Jun-Min
    Hong, Dengli
    Liang, Aibin
    Hu, Jiong
    BLOOD, 2019, 134
  • [10] Dual activating FLT3-ITD/TKD mutations found in patients with AML induce resistance to FLT3 PTK inhibitors and daunorubicin by upregulation of Bcl-xL.
    Bagrintseva, K
    Geisenhof, S
    Schwab, R
    Eichenlaub, S
    Hiddemann, W
    Spiekermann, K
    BLOOD, 2003, 102 (11) : 590A - 590A
12345